Megan M. Martin

Megan M. Martin

Auto-generated profile, based on publicly available information

Megan M. Martin

Bionano Genomics, Lineagen Division, Inc., San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
Edward Robert WassmanEdward Robert Wassman
Edward Robert Wassman
KHKaren Ho
Karen Ho
DBDiana Bertrand
Diana Bertrand
KDKyle Davis
Kyle Davis
MMMegan M. Martin
Megan M. Martin
CHCharles H. Hensel
Charles H. Hensel
Objective To evaluate a new tool to aid interpretation of copy number variants (CNVs) in individuals with neurodevelopmental disabilities. Methods Critical exon indexing (CEI) was used to identify genes with critical exons (CEGs) from clinically reported CNVs, which may contribute to neurodevelopmental disorders (NDDs). The 742 pathogenic CNVs and 1,363 variants of unknown significance (VUS) identified by chromosomal microarray analysis in 5,487 individuals with NDDs were subjected to CEI to identify CEGs. CEGs identified in a subsequent random series of VUS were evaluated for relevance to CNV interpretation. Results CEI identified a total of 2,492 unique CEGs in pathogenic CNVs and 953 in VUS compared with 259 CEGs in 6,965 CNVs from 873 controls. These differences are highly significant (p < 0.00001) whether compared as frequency, average, or normalized by CNV size. Twenty-one percent of VUS CEGs were not represented in Online Mendelian Inheritance in Man, highlighting limitations of existing resources for identifying potentially impactful genes within CNVs. CEGs were highly correlated with other indices and known pathways of relevance. Separately, 136 random VUS reports were reevaluated, and 76% of CEGs had not been commented on. In multiple cases, further investigation yielded additional relevant literature aiding interpretation. As one specific example, we discuss GTF2I as a CEG, which likely alters interpretation of several reported duplication VUS in the Williams-Beuren region. Conclusions Application of CEI to CNVs in individuals with NDDs can identify genes of potential clinical relevance, aid laboratories in effectively searching the clinical literature, and support the clinical reporting of poorly annotated VUS.

26 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Edward Robert WassmanEdward Robert Wassman
Edward Robert Wassman
MMMegan Martin
Megan Martin
JSJoseph Schauer
Joseph Schauer
JWJudy Van de Water
Judy Van de Water
MPMichael Paul
Michael Paul
Background/Objectives: Maternal Autoantibody-Related Autism (MARA) is a recently defined subset of autism characterized by specific combinations of maternal autoantibodies which cross the placenta and bind neurodevelopmentally critical target proteins. A clinical multi-ELISA MARA assay was recently rigorously analytically validated. The primary objective of this study was to assess the potential performance of this MARA autoantibody assay for predicting autism risk in high-risk populations. Secondary objectives were to establish the significant MARA autoantibody combinations and verify clinical discrimination in an external cohort. Methods: Bio-banked plasma samples from mothers of 420 autism and 335 typically developing (TD) children were analyzed by ELISA for MARA autoantibodies in combination. “Transcendent” autoantibody pairwise combinations were identified in discovery where both autoantibodies in a combination exceeded the values of every control participant. Permutation testing was used to establish that the probability of observed results significantly exceeded chance. Performance was then validated in an independent cohort (mothers of 42 autistic and 90 TD children). Results: “Transcendent” antibody levels were discovered in 70 mothers (16.7% of autism cases; no typically developing participants) in the discovery cohort. Specificity and positive predictive values for autism were 100% by construct. An external cohort showed similar performance with 14 (33.3%) transcendents. Permutation testing of each cohort demonstrated probabilities of transcendent cases to be significantly higher than expected be chance. Conclusions: The data reported here provides evidence for a high-risk subset of mothers of children with autism identified by the MARA autoantibody assay which enables further clinical validation.

26 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Edward Robert WassmanEdward Robert Wassman
Edward Robert Wassman
MMMegan Martin
Megan Martin
JSJoseph Schauer
Joseph Schauer
JWJudy Van de Water
Judy Van de Water
MPMichael Paul
Michael Paul
Background/Objectives: Specific combinations of maternal autoantibodies targeting fetal brain proteins are associated with Maternal Autoantibody-Related Autism (MARA), a biologically defined subset of autism. We previously translated a multi-ELISA assay to detect MARA-associated autoantibodies and identify mothers with transcendent levels of specific autoantibody combinations that exceed that of controls and are highly predictive of autism in their offspring. Our objective here was to derive a rule-based classifier, a “test table” of autoantibody pairwise combinations, each with pair-specific thresholds, and to validate its clinical performance characteristics by cross-validation. Methods: Plasma samples from mothers of 482 autism and 425 typically developing children were analyzed in a clinical lab for previously identified predictive combinations of autoantibodies. Stratified 20-fold cross-validation in all 907 participants assessed test table stability and predictive performance. The most stable test table was retrained on the full cohort to establish optimal thresholds and determine performance. Permutation testing assessed performance relative to chance. Results: Cross-validated performance showed a mean specificity across folds of 99.8%, an imputed mean PPV of 97.5%, a detection rate of 4.4%, and a positive likelihood ratio (LR+) of 18.5. Applied in-sample to the full cohort, the final test table detected 6.2% of cases with no false positives, giving an upper-range LR+ estimate of 26.5. Conclusion: The high specificity, PPV, and positive likelihood ratio of this assay support its potential clinical implementation for identifying a subset of mothers at very high risk of having a child with autism, and as a companion diagnostic for interventions targeting the MARA subtype of autism.

6 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KDKyle Davis
Kyle Davis
CBColleen G. Bilancia
Colleen G. Bilancia
MMMegan Martin
Megan Martin
Rena VanzoRena Vanzo
Rena Vanzo
MRMegan Rimmasch
Megan Rimmasch
MSMoises Serrano
Moises Serrano
To identify and prioritize candidate disease genes of the central nervous system (CNS) we created the Neurogenetic Systematic Correlation of Omics-Related Evidence (NeuroSCORE). We used five genome-wide metrics highly associated with neurological phenotypes to score 19,598 protein-coding genes. Genes scored one point per metric, resulting in a range of scores from 0-5. Approximately 13,000 genes were then paired with phenotype data from the Online Mendelian Inheritance in Man (OMIM) database. We used logistic regression to determine the odds ratio of each metric and compared genes scoring 1+ to cause a known CNS-related phenotype compared to genes that scored zero. We tested NeuroSCORE using microarray copy number variants (CNVs) in case-control cohorts, mouse model phenotype data, and gene ontology (GO) and pathway analyses. NeuroSCORE identified 8,296 genes scored ≥1, of which 1,580 are “high scoring” genes (scores ≥3). High scoring genes are significantly associated with CNS phenotypes (OR=5.5, p <2×10 −16 ), enriched in case CNVs, and enriched in mouse ortholog genes associated with behavioral and nervous system abnormalities. GO and pathway analyses showed high scoring genes were enriched in chromatin remodeling, mRNA splicing, dendrite development, and neuron projection. OMIM has no phenotype for 1,062 high scoring genes (67%). Top scoring genes include ANKRD17, CCAR1, CLASP1, DOCK9, EIF4G2, G3BP2, GRIA1, MAP4K4, MARK2, PCBP2, RNF145, SF1, SYNCRIP, TNPO2 , and ZSWIM8 . NeuroSCORE identifies and prioritizes CNS-disease candidate genes, many not yet associated with any phenotype in OMIM. These findings can help direct future research and improve molecular diagnostics for individuals with neurological conditions.